BCB
VRTX icon

Brian C. Broderick’s Vertex Pharmaceuticals VRTX Stock Holding History

Brian C. Broderick’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.71M Buy
19,549
+893
+5% +$396K 1.5% 23
2026
Q1 		$8.33M Buy
18,656
+1,454
+8% +$678K 1.54% 24
2025
Q4 		$7.8M Sell
17,202
-49
-0.3% -$21.1K 1.47% 25
2025
Q3 		$6.76M Sell
17,251
-420
-2% -$176K 1.28% 29
2025
Q2 		$7.87M Sell
17,671
-330
-2% -$152K 1.56% 25
2025
Q1 		$8.73M Buy
18,001
+1,127
+7% +$525K 1.78% 23
2024
Q4 		$6.8M Buy
16,874
+5,414
+47% +$2.51M 1.33% 27
2024
Q3 		$5.33M Buy
11,460
+3,876
+51% +$1.86M 1.04% 33
2024
Q2 		$3.55M Buy
7,584
+5,473
+259% +$2.38M 0.73% 35
2024
Q1 		$882K Buy
+2,111
New +$892K 0.19% 62

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Brian C. Broderick's VRTX Position: Q2 2026 in Review

Brian C. Broderick increased its Vertex Pharmaceuticals (VRTX) stake by 4.8% in Q2 2026, buying an estimated $396K and bringing the position to 19,549 shares worth $9.71M. The position accounts for 1.5% of the portfolio, ranked #23.

Brian C. Broderick first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Brian C. Broderick held 19,549 shares of Vertex Pharmaceuticals worth $9.71M as of Q2 2026.
  • Brian C. Broderick bought 893 Vertex Pharmaceuticals shares in Q2 2026, an estimated $396K.
  • Vertex Pharmaceuticals made up 1.5% of Brian C. Broderick's portfolio in Q2 2026, its #23 holding.
  • Brian C. Broderick first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Brian C. Broderick's 13F filing for Q2 2026, filed 11 Aug 2026.